Is drotaverine appropriate for treating intestinal colic, epigastric cramping, and renal colic?

Drotaverine for Intestinal Colic, Epigastric Pain, and Renal Colic

Drotaverine is an effective and safe option for treating intestinal colic and renal colic, with strong evidence supporting its use in both conditions, though it is not mentioned in current European urology guidelines which prioritize NSAIDs as first-line therapy for renal colic.

Renal Colic

For renal colic, the 2025 European Association of Urology guidelines strongly recommend NSAIDs (diclofenac, ibuprofen, metamizole) as first-line treatment 1. NSAIDs reduce the need for additional analgesia compared to opioids and work by reducing inflammation and lowering pressure in the urinary collecting system 2.

However, drotaverine demonstrates non-inferior efficacy to diclofenac for renal colic pain relief. In a randomized controlled trial, intramuscular drotaverine 80 mg achieved 52.4% pain reduction at 30 minutes and 61.3% at 60 minutes, comparable to diclofenac's 49% and 60.4% respectively 3. Another placebo-controlled study showed drotaverine was effective in 79% of patients versus only 46% with placebo (P < 0.001) 4. The most recent Cochrane review confirms NSAIDs reduce pain by approximately 3.84 cm on VAS at 30 minutes compared to placebo 2.

Clinical Algorithm for Renal Colic:

• First-line: NSAIDs (diclofenac 75 mg IM or ibuprofen IV) per guideline recommendations 1
• Alternative or add-on: Drotaverine 80 mg IM/IV when NSAIDs are contraindicated (renal impairment, GI bleeding risk, cardiovascular disease) or as combination therapy 3, 4
• Second-line: Opioids (avoid pethidine; use tramadol, hydromorphine) 1

Important caveat: NSAIDs carry significant risks including GI ulceration, bleeding, acute renal failure, and cardiovascular events, particularly at higher doses and in elderly patients 5. Drotaverine offers a safer profile with primarily minor side effects (transient hypotension, vertigo, nausea) 4.

Intestinal Colic and Abdominal Cramping

For intestinal colic and IBS-related cramping, drotaverine demonstrates superior efficacy compared to other antispasmodics and should be considered first-line therapy.

Multiple high-quality RCTs establish drotaverine's effectiveness:

• Versus mebeverine: Drotaverine 80 mg TID achieved 74% reduction in pain severity versus 46.1% with mebeverine, with significant improvement starting from day 3 (P < 0.01) 6
• Versus placebo: Pain frequency decreased in 77.7% of drotaverine patients versus 30.6% with placebo at 4 weeks (P < 0.01) 7
• Chinese population study: Drotaverine significantly improved VAS scores, stool frequency, and Bristol scores compared to placebo 8

The mechanism involves phosphodiesterase-4 inhibition, enhancing cAMP-dependent smooth muscle relaxation 9. Notably, drotaverine works synergistically with the cAMP pathway activated by forskolin, providing complementary action to anticholinergics like hyoscine butylbromide 9.

Clinical Algorithm for Intestinal Colic/IBS Cramping:

• First-line: Drotaverine 80 mg TID, taken 1 hour before meals for 4 weeks 6, 7
• Combination therapy: Consider adding hyoscine butylbromide for complementary mechanism (one stimulates cAMP pathway, the other blocks excitatory pathways) 9
• Alternative: Peppermint oil shows synergistic effects with hyoscine butylbromide 9

Epigastric Pain

For isolated epigastric pain without cramping/spasm, the evidence is less specific. At therapeutic concentrations, drotaverine does not directly modify gastric motility 9. The drug is primarily effective for spasmodic pain rather than inflammatory or ulcer-related epigastric pain.

Approach to Epigastric Pain:

• If spasmodic/cramping quality: Drotaverine 80 mg TID is appropriate 10
• If inflammatory/ulcer-related: Address underlying cause; acetaminophen or NSAIDs may be more appropriate 11
• Real-world data: 74% of patients use drotaverine for pain and 67% for cramps, with 98% satisfaction and mean severity reduction of ~5 points on 0-10 scale 10

Safety Profile

Drotaverine demonstrates excellent tolerability across all studies with no serious adverse events reported 3, 4, 6, 8, 7. Minor side effects include transient hypotension, vertigo, and nausea, none requiring treatment discontinuation 4. This contrasts sharply with NSAID risks of GI bleeding (dose-dependent, up to 25% in elderly with history of peptic ulcer disease at high doses), renal failure, and cardiovascular events 5.

Critical pitfall: The FDA drug label information provided 5 actually describes ketorolac (an NSAID), not drotaverine, highlighting the importance of verifying drug-specific safety data.

Practical Recommendations

Drotaverine 80 mg should be administered three times daily, ideally 1 hour before meals for intestinal symptoms 6. For acute renal colic, single IM/IV doses of 80 mg can be repeated once if needed 3, 4. The drug is widely used in real-world practice, with 83% of patients purchasing it without physician advice and reporting high satisfaction 10. General practitioners perceive it as more useful, effective, and tolerable than other antispasmodics for abdominal pain 10.